Skip to main content

Table 1 Study characteristics

From: Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

  Total number of included studies Hong [29] Kaneda [33] Kernan (IRIS) [2] Lee [30] Nishio [34] Nissen (PERISCOPE) [9] Suryadevara [31] Takagi (POPPS) [32] Tanaka (J-SPIRIT) [8] Dormandy (PROactive) [10, 35, 36]
Population
 Type 2 diabetes + CVD 7 X    X X X X X   X
 Type 2 diabetes + no diabetes + CVD 1   X         
 Abnormal glucose metabolism without diabetes + CVD 2    X       X  
 Patients undergoing PCI 5 X X   X X    X   
Type of pioglitazone treatment
 Pioglitazone 15 mg/d 2 X    X       
 Pioglitazone 30 mg/d 3      X   X X   
 Pioglitazone 45 mg/d 1    X        
 Pioglitazone 15–30 mg/d 2   X        X  
 Pioglitazone 15–45 mg/d 2       X     X
Treatment in control group
 None 4   X    X    X X  
 Placebo 5 X   X X    X    X
 Glimepiride 1       X     
Extracted outcome of interest
 Major adverse c cardiac/Cardiovascular disease 8 X X X X X X   X   X
 Myocardial infarction 8 X X X X X X   X   X
 Stroke 4    X    X    X X
 All-cause mortality 8   X X X   X X X X X
 Heart failure 6 X X X    X   X X X
  1. CVD cardiovascular disease, PCI percutaneous coronary intervention